This project was submitted in the following language: English (en).
Seal of excellence

Cur síos ar an tionscadal

An immersive 3D technology to assess and improve children’s visual dysfunctions at an affordable price.Our team has more than 25 years experience in the sector and co-designed with the prescribers.B2B

In Europe, are 152 Mio children. 15 Mio of these children are affected with severe visual dysfunctions. Visual dysfunction means children who can see double, and/or when reading, their eyes jump around. Current optometric solutions are expensive, subjective and manual.
WIVI is an assessment and treatment tool for visual dysfunctions personalized for each user and the specialist, which provides a complete cognitive, objective, real time based on scientific evidence with AI awarded by IBM Watson.


CEO & Co-Founder

Ms. Eva Garcia Ramos, CEO & Co-Founder: Business, technology and company operations. LinkedIn profile:ía-ramos Eva is a Telecommunications Engineer. PDG IESE Business School. Reputation: CEO, CIO and Member of the Board of Directors with worldwide responsibilities in major companies such as Gamesa-Siemens and others. Management: Eva has gained global management experience in international companies and contributed to the development of new business lines. She has also contributed to the development of other start-ups. 24 years of experience. Managing large budgets More than 10Mios and large teams more than 100 people. Eva has been working on diferent companies: large, familiar, consultancy, startups and her own company.
Wivi has 30 people working. The co-founder Pr. Dr. Juan Carlos Ondategui, PhD, MSc, MPH. Reputation: Senior lecturer in Optometry at the Faculty of Optics and Optometry. Referee for Instrumentation. Partners: HP, IBM, ASD, UPC, EIT Health,..


Tír, Réigiún

An Spáinn [Cataluña]

An Ghearmáin

An Fhrainc

Italy, Portugal, UK, and North America

Dáta tosaigh

Aibreán 2016

Costas measta an tionscadail

EUR 5 milliún


Earnálacha digiteacha eile, ábhar agus seirbhísí san áireamh

Bonneagar sóisialta, geilleagar sóisialta agus dlúthpháirtíochta.

Úinéireacht na sócmhainní


An cineál tionscadail


Stádas an tionscadail

Beta product pre-launching in 2019

An cineál ioncaim

Bunaithe ar an margadh

Cruthú post tuartha


Réasúnú eacnamaíoch / Samhail ghnó

WIVI has been co-designed and we have validated the business model with our prescribers (the optical big chains). Is a B2B model with them. We can explain in detail.

Market: In Europe there are > 125.000 optics stored, grouped in 200 chains 60% market share. Due to the price war in their traditional business selling glasses they are anxious to find new business fields (deafness, low vision and main chain had confirmed they are interested in develop together the field of functional visual dysfunctions as a new business as well as a way to create traffic an customers loyalty).
The revenues can increase more than 15%
WIVI Benefits
-WIVI is tool with superior assess rates regarding current alternatives.
-Complete Cognitive solution with algorithtms awarded on the IBM Watson Build Competition
-Assessment and treatment on the same solution for all the areas, freedom of movement, user control(Unique). Supported by a scientific evidence.
-All tools are for 1%specialist, we focus on 98% not specialist
-Significantly reduces the treatment period.
-WIVI is a cheaper alternative, representing savings for the patient with an engaging experience
-It can measure more than 50 parameters in all areas, nowadays they measure 4 in one area

Mionsonraí an mhaoinithe

Maoiniú tionscadail a aimsíodh: EUR 1.75 milliún (35 %)

Foinse maoinithe: Príobháideach

We started working on the technology in 2016 and since then invested more than 1,2 M€ in product development (200K from the founders contribution). We have recently close a second round of financing in 2018. The German VC has invested in WIVI the 3 times time and a Spanish company 2 times and we have a commitment with them. For next round SERIE A we have half of the round already committed with them. We have obtain a ENISA loan, SME Phase1, and some EIT Health prizes and grants.

Tá maoiniú a bhaineann leis an tionscadal seo faighte ag an tionscnóir ón Aontas Eorpach / ón mBanc Eorpach Infheistíochta nó tá iarratas déanta aige ar an maoiniú sin.

Baic fhéideartha/ Rioscaí féideartha

Underestimated cost calculation (financial risk) ●Level of Impact: Medium (M) ● Level of Likelihood: Low (L)
Delays in project ● Level of Impact: High (H) ● Level of Likelihood: M
Certification Problems ● Impact: H ● Likelihood: L
Being unknown on the market ●Impact: H ● Likelihood: M
Competitor product development ● Impact: M ● Likelihood: M
Employment of appropriate technical personnel ● Impact: L ● Likelihood:L
For the risks we have an a action plan to mitigate them according to SME phase1

Eolas breise faoin tionscadal

AWARDS: WIVI was selected by at the EIC innovation Forum in Berlin (Sep 2018). WIVI was selected as European semifinalist in the IBM’s Watson Build 2018 Award and European Finalist andas Spanish winner in the Watson Build 2017(for the cognitive algorithms and the innovation). WIVI is supported by EIT Health and was selected as fisrt prize in EIT Health Headstart 2018 after being European finalist for the EIT Health Catapult 2017 (Dec 2017) as Spanish winner in Digital Health. Selected as European finalist 1 of 10 in Health in the South Summit (Oct 2018) from 3.500 companies from 70 countries. Selected as European finalist in Next Women (Amsterdam, Oct 2018), Second prize in Girls in Tech Innovation Paris-Singapore (Oct 2018), etc...

Foilsiú: 21/05/2019 | An nuashonrú is déanaí: 21/05/2019

Ní thugann an Coimisiún aon bharánta ná ní dhéanann aon uiríoll, cibé acu go follasach nó go hintuigthe é, go bhfuil an Fhaisnéis Tionscadail saor ó earráidí. Cuirtear an Fhaisnéis Tionscadail ar fáil gan aon ghealltanais, coinníollacha nó barántaí i dtaobh chruinneas na faisnéise sin.